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Parkinson’s disease is the second most common neurodegenerative disorder, with 1-2% 
of the population over 65 years old being affected (Felice,2016).  Parkinson’s disease is 
characterized by loss of midbrain dopaminergic neurons and accumulation of alpha-synuclein 
aggregates, throughout the CNS and ENS, which may use the Vagus nerve as a path to spread 
from the ENS to the brain (Perez-Pardo,2017). 
Parkinson’s disease non-motor symptoms include cognitive impairment, depression, 
apathy, pain, sleep disturbances, olfactory impairment, and GI dysfunction.  Motor symptoms 
include rigidity, bradykinesia, and tremor, due to the dopamine deficit in basal ganglia 
(Caputi,2018).  This dysfunction of the GI tract has led research into the possible connections 
between the gut microbiome and the pathogenesis of CNS diseases through the gut 
microbiota-brain axis. 
The gut microbiota-brain axis is a two way communication route between the microbiota 
and the brain.  This axis includes the gut microbiota and their metabolic products, the ENS, the 
SNS, the PNS, neural-immune system, tryptophan metabolism, Vagus nerve, neuroendocrine 
system, and the CNS.  The metabolites produced by the microbiota include short chain fatty 
acids, branched chain amino acids, and peptidoglycans (Cryan,2019). The gut microbiota has 
many functions, some of which include: forms the intestinal epithelial barrier, produces mucus, 
produces anti-microbial substances, and promotes nutrient absorption(Wang, 2013).  The 
microbiome forms brain function by taking components of the diet and producing metabolites 
from those components (Ezra-Nevo,2020).  
It has been found through studies that dysbiosis of the microbiome and gut 
hyper-permeability are contributing factors to CNS pathogenesis, such as PD (Wang,2013).  A 
few other diseases have been linked back to an imbalance of the gut microbiome and those 
include depression, anxiety, IBS, and IBD (Bear,2020).  Research has shown that certain 
infections, antibiotics, illness, age, environmental stressors, genetics and diet may cause changes 
in the microbiome that can cause progression of CNS diseases (Cryan,2019).  
Currently, Levodopa is the “gold standard” for treatment of patients with PD, but this 
form of treatment does not treat the non-motor symptoms of the disease, such as, bloating, 
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drooling, constipation, nausea, delayed gastric emptying, and prolonged intestinal transit time 
(Perez-Pardo,2017).  
Studies are now further looking into the role nutrition and probiotics may play in slowing 
or stopping the pathogenesis of Parkinson’s disease.  Parkinson’s disease has a strong 
environmental component, with only 10% of cases being hereditary (Sampson,2017).  A new 
treatment by supplements, probiotics, and modifying a patient’s diet would be much more 
accessible to many patients than the current treatment, as well as have fewer or no side effects 
(Uyar,2019).  Even used as an additional treatment with medication, nutrition could help reduce 
the severity of symptoms experienced that are not treated by levodopa, as well as possibly 
enhance the beneficial effects of levodopa (Perez-Pardo,2017). 
 
Current treatment of Parkinson’s 
Currently Parkinson’s disease is being treated with levodopa, a precursor to dopamine. 
Levodopa is converted to dopamine by DOPA decarboxylase and is used to control the 
bradykinetic symptoms in PD, but does not treat the non-motor symptoms of the disease 
(NCI,2020).  These non-motor symptoms, such as cognitive impairment, depression, sleep 
disturbances, and GI dysfunction can cause a significant decrease in quality of life and should be 
treated along with the motor symptoms (Caputi,2018).  Some symptoms patients display can be 
either from the disease itself, or can be caused by the treatment (Rektorova,2019).  Levodopa is 
used as a treatment for 85% of PD patients, but using it for a prolonged period of time can cause 
dyskinesia and motor fluctuation, and the patient may also develop resistance to the drug 
(Perez-Pardo,2017).  It is important to find new ways to manage PD to decrease all symptoms, 
especially ones that are caused by current treatments. 
Levodopa is a common treatment for PD and is considered the “gold standard” for the 
disease.  However, it is important to take all symptoms into account and possibly use several 
forms of treatment to manage the whole disease, and not just parts of the disease.  Controlling 
motor-symptoms is vital for patients, but it is also important to look at other issues patients face 
and manage those as well, as they can greatly influence a patient’s quality of life. 
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Parkinson’s disease and diet 
There are currently no medical diets or restrictions for patients with Parkinson’s disease, 
but more research is looking at the connections between diet, changes in the microbiome, and the 
pathogenesis of Parkinson’s disease.  The interactions between diet, microbiome, and host 
provide an outline to understand how the gut-brain axis functions (Ezra-Nevo,2020).  
Unbalanced nutrition, among other things, such as medication, age, or stress can change 
microbial metabolites, which then can trigger accumulation of alpha-synuclein in the intestinal 
mucosal wall (Uyar,2019).  The alpha-synuclein aggregates most likely begin with the innate 
immune system being overstimulated due to either gut dysbiosis or SI bacterial overgrowth 
(Caputi,2018).  Alpha-synuclein pathology does not need a pathogenic or environmental trigger 
since it can be started by the patient’s own enteric microbiota (Caputi,2018).  These differences 
trigger local and systemic inflammation, which in turn causes enteric neuroglial activation, and 
then the development of alpha-synuclein aggregates (Caputi,2018).  Changes in alpha-synuclein 
are significant in the pathogenesis of PD, and can be considered the “cardinal neuropathological 
feature in PD” (Felice,2016).  Further proof that alpha-synuclein aggregates contribute to this 
disease was a study that demonstrated “alpha-synuclein overexpressing mice showed progressive 
deficits in motor function and also displayed defects of gut motility”(Sampson,2017).  This 
solidifies the idea that uncontrolled alpha-synuclein expression in humans is associated with a 
higher risk of PD (Sampson,2017).  A study by Samson shows that when microbiota from PD 
patients was transplanted into mice these mice showed increased alpha-synuclein-mediated 
motor dysfunction compared to mice who had a healthy patient’s microbiota transplanted into 
them (Sampson,2017).  This study as a whole causes researchers to consider that alpha-synuclein 
overexpression and dysbiosis work together and impact disease outcomes (Sampson,2017). 
These aggregates of alpha-synuclein are present in the ENS before they are present in the brain, 
suggesting a “prion-like” spread from the ENS to the CNS (Felice,2016).  Specifically, 
alpha-synuclein aggregations were found in intestinal mucosa and salivary glands, sometimes at 
least a decade before the beginning of PD motor symptoms (Lange,2019).  
Gut microorganisms and their metabolites begin the immune response, which then causes 
an inflammatory response and causes the misfolding of alpha-synuclein (Ma,2019).  This 
5 
inflammatory response also serves to start the complement pathway, which can cause damage to 
dopaminergic neurons, causing CNS dysfunction and neurological dysfunction, a key component 
of developing PD.  Inflammation that results from changes in the microbiome can cause 
increased gut permeability as well as increased permeability of the blood-brain barrier 
(Ma,2019). 
 
Source: Perez-Pardo,2017: Alpha synuclein aggregates spreading from the ENS to the 
CNS.  The vagus nerve may be the path for the spread of alpha-synuclein. 
 
A specific component of this inflammation is LPS, which has been found to disrupt the 
BBB and promotes neuroinflammation, which causes damage (Caputi,2018).  These different 
factors could suggest that “...the neurodegenerative cascade may actually be initiated in the gut 
with subsequent spreading to the brain…”(Scheperjans,2016).  
Certain studies have looked at different aspects of diet to see which diets are related to 
progression of PD and which diets are not. A diet that was associated with a reduced PD 
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progression rate had higher amounts of fresh vegetables, fresh fruit, nuts, seeds, non-fried fish, 
coconut oil, and olive oil.  A diet associated with a more rapid PD progression included canned 
fruits and vegetables, diet or non-diet soda, fried food, beef, ice cream, yogurt, and cheese. 
However, “statistically significant associations could not be found between most food groups 
assessed and the incidence of PD” (Lange,2019).  More research is needed in this field to find 
any definitive answer, but a healthy diet is more likely to support a healthy microbiome. A diet 
that follows these guidelines and has been shown to have a decreased association with PD is the 
Mediterranean diet (Lange,2019).  
Additionally, ketogenic diets could have some therapeutic use for patients with 
neurodegenerative diseases.  A ketogenic diet is high in fat and low in carbs.  The ketones 
produced could enhance mitochondrial oxidative phosphorylation in the brain.  In a study of a 
group on a ketogenic diet and a group not on a ketogenic diet, the ketogenic group showed more 
improvements in non-motor symptoms than the non-ketogenic group.  These results are not 
definitive and require further study to assess them more completely (Lange,2019). 
Certain components of a diet are also important for a healthy microbiome and healthy, 
functioning cells.  A few of these components include fiber and fatty acids.  Having adequate 
fiber in the diet is beneficial for the microbiome and could slow the progression of PD. Fatty 
acids are also of significance in that they are essential for neuronal structure and function.  Fatty 
acids are also anti-inflammatory, antioxidative, and neuroprotective, all properties that could 
benefit a patient with PD (Uyar,2019). 
Besides fatty acids, “DHA and choline are phospholipid precursors needed for formation 
and maintenance of neuronal membranes” (Perez-Pardo,2017).  Nutritional intervention that 
contains DHA and choline can raise these levels and cause an increase in phospholipid synthesis. 
DHA is also important because it inhibits Toll-like receptor (TLR)-mediated proinflammatory 
pathways.  TLR activation brings about the inflammatory response that precedes neuron loss and 
stopping this TLR response slows the progression of PD (Caputi,2018).  Toll-like receptors are 
triggered when there is dysbiosis of the gut microbiota and when the gut epithelial barrier is 
disrupted.  When these TLRs are activated, they activate downstream signaling pathways.  These 
pathways advance inflammation and increase oxidative stress in the gut and brain of patients 
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with PD (Caputi,2018).  It is believed that TLR2 and TLR4 are the most involved in the 
development of PD, so finding specific ways of targeting them would be beneficial to delay 
symptoms of PD (Caputi,2018). 
 
 
Source: ​Ambrosini, Y. Healthy gut microbiota contributes to healthy behavior, clearance of 
proteins from the brain, and a response to immune stimulation.  Dysbiosis of the gut microbiota 
can cause increased GI permeability and can lead to dementia, depression, and anxiety. 
 
Besides diet, it may be possible that supplements and vitamins could help reduce 
symptoms or slow the progression of PD.  Some studies demonstrated that PD patients had lower 
serum vitamin D levels than non-PD patients.  Vitamin D is required for brain development and 
function.  At the moment it is not understood if the low vitamin D is a cause, correlate, or a 
consequence of PD (Lange,2019). 
Additionally, Omega-3 fatty acids and vitamin B1 are necessary for oxidative stress and 
metabolism.  Supplementation of these can upregulate anti-apoptotic proteins and improve 
oxidative metabolism (Lange,2019; Uyar,2019). 
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An important factor to keep in mind is that non-motor symptoms of PD may precede 
motor symptoms by many years.  In the premotor period lifestyle-related factors may advance 
the progression of PD (Lange,2019).  Managing these symptoms can be helped by altering the 
diet and including pre and probiotics.  Even if altering the diet does not change the outcome of 
the prognosis, it can improve the quality of life of patients before they are even diagnosed 
(Perez-Pardo,2017). 
As different diets and supplements are being assessed, it may also be possible to develop 
medical foods for PD, which may make it easier for patients to follow a strict diet that may slow 
the progression of their disease or alleviate some severity of symptoms.  These diets could be 
formulated to balance the gut microbiota, decrease inflammation, and optimize other treatments 
being used by the patient (Morkl,2020).  
Currently there have not been statistically significant associations between most food 
groups and the prevalence of PD, but research is ongoing to find connections and possibly 
develop diets to benefit PD patients (Lange,2019).  Microbiome experiments need a high degree 
of control of the patient’s diet and very specific diet changes, both of which present considerable 
challenges for researchers in performing a successful study (Ezra-Nevo,2020).  Even through 
these challenges, it could be possible to use nutrition as a potential therapy (Morkl,2020). 
 
Parkinson’s disease and probiotics 
Since there are connections being found between the gut and the brain in 
neurodegenerative diseases, it is important to find ways to supplement good bacteria and to 
inhibit pathogenic bacteria.  One of these ways could be to put prebiotics and probiotics to work. 
Prebiotics and probiotics could complement the current therapies that are being used for PD. 
Microbial metabolites activate immune cells, such as microglia.  Microglia protect the 
brain through involvement in immune response, phagocytosis, and the production of cytokines. 
They also play a part in regulating synaptic transmission, synaptic pruning, and neuronal circuit 
formation.  It is vital to have a healthy microbiome in order to protect these microglia (Ma,2019). 
Specifically, different probiotic combinations can counteract the deficient neurogenesis that 
precedes/accompanies the development of PD (Ma,2019). 
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Probiotics from Lactobacillus and Bifidobacterium have many functions that include: 
enhancing intestinal epithelial integrity, protection from gut barrier disruption, regulating 
mucosal immune system, and inhibiting pathogenic bacterial growth (Caputi,2018).  Lactobacilli 
and Bifidobacteria have been found to be important elements of anti-inflammatory probiotic 
mixtures (Wang,2013).  Lactobacilli specifically has been shown to alleviate CNS inflammation 
(Ma,2019). 
Mice that were fed probiotics showed fewer depressive and anxiety behaviors, which can 
be non-motor problems for patients with PD. Mice that lacked microflora displayed more 
neurological issues in emotional behaviors, learning, and memory (Ma,2019).  Through studies it 
has been found that “it is possible to modulate brain function by improving anxiety and 
depression using probiotics” (Perez-Pardo,2017).  Research has also suggested that these forms 
of dietary intervention could be used as an alternative therapy or as an addition to already in 
place therapies for patients (Bear,2020).  
Additionally, PD patients have been found to have decreased amounts of short chain fatty 
acid butyrate-producing bacteria.  Short chain fatty acids are needed to maintain intestinal 
epithelial integrity and to regulate mucosal immunological responses.  Prevotella is a bacteria 
that has been found in low amounts in 77.6% of  PD patients (Perez-Pardo,2017).  Prevotella is 
involved in mucus formation of the gut and production of short chain fatty acids through fiber 
fermentation in the large intestine (Perez-Prado,2017).  SCFAs from these fibers are needed to 
maintain intestinal epithelial integrity as well as to regulate mucosal immunological responses 
(Perez-Prado,2017).  Low amounts of Prevotella could cause hyperpermeability of the gut and 
induce changes in the ENS, possibly contributing to gut dysmotility. The researchers were able 
to correct this with prebiotic fibers (Perez-Pardo,2017).  
Besides helping to balance out the gut microbiome in patients, treatment with probiotics 
may also be able to help the treatment of levodopa to be more effective.  Probiotics help to 
restore gut function.  This restoration could cause levodopa to be better absorbed by the patient 
and in turn have more positive effects for those patients (Caputi,2018; Perez-Pardo,2017). 
Although the association between diet and depression has conflicting results and limited 
research dedicated to it, diet is one of the most important components that affects the microbiota 
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and solidifying the link between diet, microbiota, and CNS diseases should be important in 
future research (Bear,2020). 
 
Conclusion 
It is well accepted that the gut and brain communicate between many pathways and 
systems of the body and that changes in the microbiome can cause a multitude of health issues, 
such as depression, anxiety, IBS, and IBD (Bear,2020).  There is less conclusive evidence that 
this same dysbiosis of the gut microbiome causes Parkinson’s disease, but the accumulation of 
alpha-synuclein in the ENS and CNS points to this as a possible factor in Parkinson’s disease 
(Felice,2016).  All studies included in this review agree that the microbiome is disrupted in PD 
patients, but it is unclear which types of bacteria are causing this progression or whether the 
disruption is the cause or result of PD. 
Throughout multiple studies, PD patients (70-80%) reported having GI dysfunction 
before developing motor symptoms of the disease, and sometimes GI symptoms appeared 
decades before the motor symptoms (Perez-Pardo,2017).  If these GI symptoms are addressed 
earlier, either through probiotics or change in diet, it may be possible to slow down or possibly 
stop the progression of the disease. Besides diet, age also has been shown to cause changes in the 
microbiome, suggesting that it may be beneficial to help older generations with better nutrition 
and probiotics as a precautionary measure (Cryan,2019). 
Even if GI dysfunction is not addressed and PD develops in the patient, better nutrition 
and probiotics may be beneficial by allowing levodopa to be absorbed more efficiently, which 
would improve the behavioral and cognitive functions in PD patients (Caputi,2018). 
At the moment, the go to treatment for PD patients in levodopa. Unfortunately, this 
method does not treat the non-motor symptoms of the disease and has its own shortcomings as 
well.  
Studies are being done on the impact diet can have on current PD patients.  Different 
foods have been shown to slow or accelerate the progression of PD, although this has not been 
one hundred percent proven (Lange,2019).  There is still much research to be done on how diet 
can change or prevent the progression of PD, but it is agreed throughout all studies in this review 
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that diet does affect the microbiome of the gut.  Currently more nutritional studies are being 
done, as well as studies with probiotics and developing medical foods for patients with PD 
(Lange,2019). 
Most likely it would be most helpful to include a nutritious diet along with medication in 
order to allow increased absorption of the treatment, as well as treat some of the GI symptoms in 
patients.  Overall, a balanced diet may not significantly improve symptoms of PD, but it would 
also not hurt the patient and may provide some relief and increased quality of life. 
Some specific areas of research that should be addressed include how microbiota affects 
microglia activation, cellular protein clearance pathways and neurotransmitter production 
(Sampson,2017). Having a bigger picture of how one aspect of the disease plays into many other 
dimensions of the disease will help to give a clearer picture of the pathogenesis and possible 
treatments for PD. 
Additionally, identifying specific bacteria and microbial metabolites that are different 
between PD patients and healthy patients could potentially act as disease biomarkers, or even 
targets for medication.  Safe and effective therapies could be developed to correct the dysbiosis 
and slow or even stop the advancement of motor symptoms that severely limit the quality of life 















Ambrosini, Y., Borcherding, D., Kanthasamy, A., Kim, H., Willette, A., Jergens, A., Allenspach, 
K. and Mochel, J., 2019. The Gut-Brain Axis in Neurodegenerative Diseases and Relevance of 
the Canine Model: A Review. ​Frontiers in Aging Neuroscience​, 11. 
 
Bear, TLK., Dalziel, JE., Coad,J., Roy, NC., Butts,CA., Gopal,PK., 2020. The Role of the Gut 
Microbiota in Dietary Interventions for Depression and Anxiety. ​Advances in Nutrition​. 
 
Caputi, V. and Giron, M., 2018. Microbiome-Gut-Brain Axis and Toll-Like Receptors in 
Parkinson’s Disease. ​International Journal of Molecular Sciences​, 19(6), p.1689. 
 
Cryan, JF., O’Riordan, KJ., Cowan, C., Sandhu, KV., Bastiaanssen, TF., Boehme, M., 
Codagnone, MG., Cussotto, S., Fulling, C., Golubeva, A., Guzzetta, KE., Jagger, M., 
Long-Smith, CM., Lyte, JM., Martin, JA., Molinero-Perez, A., Moloney, G., Morelli, E., 
Morillas, E., O’Connor, R., Cruz-Pereira, JS., Peterson, VL., Rea, K., Ritz, NL., Sherwin, E., 
Spichak, S., Teichman, EM., Van de Wouw, M., Ventura-Silva, AP., Wallace-Fitzsimmons, SE., 
Hyland, N., Clarke, G., Dinan, TG., 2019. The Microbiota-Gut-Brain Axis. ​Physiological 
Reviews, ​99(4), pp.1877-2013. 
 
Ezro-Nevo, G., Henriques, SF., Ribeiro, C., 2020. The diet-microbiome tango: how nutrients 
lead the gut brain axis. ​Current Opinion in Neurobiology, ​62, pp.122-132. 
 
Felice, V., Quigley, E., Sullivan, A., O'Keeffe, G. and O'Mahony, S., 2016. Microbiota-gut-brain 
signalling in Parkinson's disease: Implications for non-motor symptoms. ​Parkinsonism & 
Related Disorders​, 27, pp.1-8. 
 
Lange, K., Nakamura, Y., Chen, N., Guo, J., Kanaya, S., Lange, K. and Li, S., 2019. Diet and 
medical foods in Parkinson's disease. ​Food Science and Human Wellness​, 8(2), pp.83-95. 
 
Ma, Q., Xing, C., Long, W., Wang, H., Liu, Q. and Wang, R., 2019. Impact of microbiota on 
central nervous system and neurological diseases: the gut-brain axis. ​Journal of 
Neuroinflammation​, 16(1). 
 
Mörkl, S., Wagner-Skacel, J., Lahousen, T., Lackner, S., Holasek, S.J., Bengesser, S.A., Painold, 
A., Holl, A.K., Reininghaus, E.Z., 2020. The Role of Nutrition and the Gut-Brain Axis in 
Psychiatry: A Review of the Literature. ​Neuropsychobiology​, 79, pp.80-88. 
 
National Cancer Institute. 2020. ​NCI Drug Dictionary​. [online] Available at: 
<https://www.cancer.gov/publications/dictionaries/cancer-drug/def/levodopa> [Accessed 1 April 
2020]. 
 
Perez-Pardo, P., Kliest, T., Dodiya, H., Broersen, L., Garssen, J., Keshavarzian, A. and 
Kraneveld, A., 2017. The gut-brain axis in Parkinson's disease: Possibilities for food-based 
therapies. ​European Journal of Pharmacology​, 817, pp.86-95. 
13 
 
Rektorova, I., 2019. Current treatment of behavioral and cognitive symptoms of Parkinson's 
disease. ​Parkinsonism & Related Disorders​, 59, pp.65-73. 
 
Sampson, T., Debelius, J., Thron, T., Janssen, S., Shastri, G., Ilhan, Z., Challis, C., Schretter, C., 
Rocha, S., Gradinaru, V., Chesselet, M., Keshavarzian, A., Shannon, K., Krajmalnik-Brown, R., 
Wittung-Stafshede, P., Knight, R. and Mazmanian, S., 2017. Gut Microbiota Regulate Motor 
Deficits and Neuroinflammation in a Model of Parkinson’s Disease. ​Cell​, 167(6), 
pp.1469-1480.e12. 
 
Scheperjans, F., 2016. Gut microbiota, 1013 new pieces in the Parkinsonʼs disease puzzle. 
Current Opinion in Neurology​, 29(6), pp.773-780. 
 
UYAR, G. and YILDIRAN, H., 2019. A nutritional approach to microbiota in Parkinson’s 
disease. ​Bioscience of Microbiota, Food and Health​, 38(4), pp.115-127. 
 
Wang, Y. and Kasper, L., 2013. The role of microbiome in central nervous system disorders. 
Brain, Behavior, and Immunity​, 38, pp.1-12. 
 
 
